EXPEDEON - Key Persons
Job Titles:
- Senior Vice President, Research & Development
Job Titles:
- Non - Executive Director
- Member of Our Board
Background/current external appointments: Bessie Lee has served as a member of our board since January 2021. Ms. Lee is based in China and is the CEO, Greater China of JonesLangLaSalle and Founder of Withinlink (Shanghai) Investment Management Co Ltd, a China-based venture capital firm and start-up incubator focused on marketing technology. Prior to this Ms. Lee spent almost three decades at WPP plc and served as CEO, China from 2013 to 2017. In addition, Ms. Lee served as CEO for Mindshare and GroupM. Ms. Lee is currently a Non-Executive Director of Electrocomponents plc, Homeplus Digital Co Ltd (formerly China Networks Systems Co Ltd) and Shanghai Fuge Information Technology Co Ltd. Ms. Lee holds a B.A. in German and English, from Wen Tzao Ursula Foreign Language College, a B.Sc. in Mass Communications and a M.S. in Communications both from Illinois State University.
Job Titles:
- Senior Vice President, Sales & Marketing
Job Titles:
- Non - Executive Director
- Senior Independent Director
- Member of Our Board
Background/current external appointments: Giles Kerr has served as a member of our board since December 2018. Mr. Kerr is currently a Non-Executive Director of Arix Bioscience plc, Senior plc and Oxford Science Enterprises (formerly known as Oxford Sciences Innovation) and is the Chairman of Paypoint plc. Since 1990, Mr. Kerr has served in a variety of increasingly senior roles at Amersham plc, including Chief Financial Officer and a board member from 1997 to 2004, when the company was acquired by GE Healthcare. Prior to his role at Amersham, Mr. Kerr was a National Partner with Arthur Andersen & Co. Mr. Kerr was Director of Finance of the University of Oxford from 2005 until 2018 and was previously a Director of Victrex plc, BTG plc, Quanta Dialysis Technologies and Elan Corporation Inc. Mr. Kerr holds a B.A. in Economics from the University of York.
Skills, experience and contribution: A Fellow of the Institute of Chartered Accountants of England and Wales with over 20 years' experience in key senior positions in a number of companies, Giles has played a pivotal role their development and growth. Giles brings his first-hand understanding of Abcam's academic research customers from his time at Oxford University.
Job Titles:
- Senior Vice President, Supply Chain & Manufacturing
Job Titles:
- Senior Vice President, Abcam Digital
Job Titles:
- Non - Executive Director
- Member of Our Board
Background/current external appointments: Luba Greenwood has served as a member of our board since September 2022. Ms. Greenwood has held a number of leadership and board positions in the healthcare, biotech, and digital health industries. Currently, Ms. Greenwood is the managing partner of the Dana Farber Cancer Institute Venture Fund, Binney Street Capital ("BSC"), a venture fund she has built and launched, and she is also the CEO of Kojin Therapeutics, a BSC portfolio company. In addition she is a Non-Executive Director of Massachusetts Biotechnology Council, Inc., BenchSci, and In8Bio Inc. Ms. Greenwood has held leadership positions at Google Life Sciences and at F. Hoffman-La Roche, from 2018 to 2019 and 2015 to 2018, respectively. She is currently a lecturer in engineering sciences at Harvard University, since 2019. Ms. Greenwood holds a law degree from Northeastern University School of Law.
Job Titles:
- Member of Our Board
- Non - Executive
Background/current external appointments: Mara Aspinall has served as a member of our board since September 2015. Ms. Aspinall is a co-founder and Managing Director of BlueStone Venture Partners, the President and CEO of Health Catalyst Group, part-time Professor of Practice, Diagnostics, College of Health Solutions, a Director of Blue Cross Blue Shield Arizona Inc., Castle Biosciences Inc., DA32, OraSure Technologies Inc. Previously, Ms. Aspinall was President and CEO of Ventana Medical Systems/Roche Tissue Diagnostic. Ms. Aspinall spent twelve years at Genzyme Corporation (now part of Sanofi) as President of Genzyme Genetics and Genzyme Pharmaceuticals. Ms. Aspinall is co-founder of the Biomedical Diagnostics program at Arizona State University, the only institution dedicated to the study of diagnostics as an independent discipline. Ms. Aspinall is also a Fellow of the American Institute for Medical and Biological Engineering. Ms. Aspinall holds a B.A. in International Relations from Tufts University and an M.B.A. from Harvard Business School. Ms. Aspinall is certified in board oversight of cybersecurity from Carnegie Mellon University.
Skills, experience and contribution: Mara contributes her considerable international experience in the biotechnology and diagnostics industries with public and private companies. Mara's specific focus areas are acquisition integration, global manufacturing, quality systems and strategic marketing.
Job Titles:
- Non - Executive Director
- Member of Our Board
Background/current external appointments: Mark Capone has served as a member of our board since January 2021. Mr. Capone is an accomplished life sciences executive. He spent over 17 years with Myriad Genetics, of which he served as CEO and President for five years and helped Myriad Genetics grow into a leading global precision medicine company. Prior to this Mr. Capone spent 17 years with Eli Lilly and Company in positions across the entire value chain. Mr. Capone is currently CEO of Precision Medicine Advisors, a consultancy for molecular diagnostics, pharmaceuticals, and biotechnology organizations, which he founded in 2020. In addition, he is a Non-Executive Director and member of the Compensation Committee for of Owlstone Medical Ltd, a breath biopsy diagnostic company focused on early detection of cancer and precision medicine, and a Non-Executive Director and member of the Audit Committee and Financing Committee of DermTech, a U.S. based company focused on early melanoma detection and other skin applications. Mr. Capone holds a B.Sc in Chemical Engineering from Pennsylvania State University and a M.Sc. in Management and a M.Sc.in Chemical Engineering from Massachusetts Institute of Technology.
Skills, experience and contribution: Mark has significant Life Science industry experience and of working in companies of different scale. He is an accomplished healthcare CEO with experience in molecular diagnostics, genetics, biotechnology, medical devices, and pharmaceuticals. He has extensive US public and private board experience across a large range of companies specializing in growth.
Job Titles:
- Senior Vice President, Human Resources
Job Titles:
- Non - Executive Chairman
- Member of Our Board
Background/current external appointments: Peter Allen has served as a member of our board since June 2018. Mr. Allen is also currently Non-Executive Chairman of Advanced Medical Solutions plc. He is a Non-Executive Director of Istesso Ltd. Mr. Allen has nearly 30 years' experience as an executive director, non-executive director and chairman in a wide range of life science companies. From 2012 to 2021, Mr. Allen served as the Chairman of Clinigen plc. From 2011 to 2022, Mr. Allen served as a non-executive director and then the Chairman of Oxford Nanopore Technologies plc. From 2015 to 2020, Mr. Allen served as the Chairman of Diurnal Group plc. From 2009 to 2012, Mr. Allen served as Chairman of Proximagen Neurosciences plc, from 2005 to 2013 he served as Chairman of ProStrakan Group plc, including as interim CEO from 2010 to 2011, and he served as CFO and Deputy CEO of Celltech Group plc from 1992 to 2004. Mr. Allen holds a BA in Accountancy and Law from the University of Kent.
Skills, experience and contribution: A chartered accountant by background, Peter brings to Abcam his experience as a chairman and board member and has substantial experience in M&A, international growth, fundraising and investor relations, as well as the commercialisation of intellectual property.
Job Titles:
- Non - Executive Director
- Member of Our Board
Background/current external appointments: Sally W. Crawford has served as a member of our board since August 2021. Ms. Crawford has held a number of senior leadership and board positions in the healthcare industry spanning more than three decades. She served as Chief Operating Officer of Healthsource Inc., a publicly held managed care organization, from its founding in April 1985 until January 1997. Ms. Crawford has extensive board experience, and currently serves on the Board of Directors of Hologic, Inc., Insulet Corporation and Prolacta Bioscience. She is also the Lead Independent Director at Hologic, Inc., the current Compensation Chair at ZimVie and Prolacta Bioscience and the former Compensation Chair at Hologic, Inc and Insulet Corporation. Ms. Crawford holds a B.A. in English from Smith College and an M.S. in Communications and Media Studies from Boston University.